



## Inhibitors in the Treatment of Cancer and Neurodegenerative Disorders

Guest Editors:

**Prof. Dr. Katarina Nikolic**

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia

**Prof. Dr. Biljana Bufan**

Department of Microbiology and Immunology, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia

**Dr. Dusan Ruzic**

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia

Deadline for manuscript submissions:

**closed (31 January 2024)**

### Message from the Guest Editors

Molecular mechanisms that underpin the onset and progression of malignant and neurodegenerative diseases seem to have little in common. Some epidemiological studies add weight to the inverse association between certain types of cancer and neurodegenerative diseases. However, there is no clear consensus on this connotation. Cancer cells escape cell death signals whereas aberrant activation of neuronal cell death is a common hallmark in neurodegenerative diseases. Numerous studies suggest common genetic and epigenetic factors that are implicated in cancer and neurodegeneration. Some of these include p53, ATM gene, Cyclin-dependent kinase 5 (CDK5), glycogen synthase kinase-3 (GSK3), histone deacetylase 2 (HDAC2), Brain-derived Neurotrophic Factor (BDNF), changes in microRNA (miRNA) expression and many more.

To improve our understanding of the crosstalk between cancer and neurodegeneration, this Special Issue aims to discuss the novel therapeutic agents able to target aberrant molecular mechanisms common in cancer and neurodegenerative diseases.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Patrick J. Sinko**

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceutics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma